Last reviewed · How we verify

NCT05532592

Investigation on the Hesitancy of COVID-19 Vaccination Among Liver Transplant Recipients in China

Completed Last updated 8 September 2022
What this trial tests

trial testing Perceptions and attitudes towards COVID-19 and COVID-19 vaccine in Vaccine Hesitancy in 449 participants. Completed in 30 May 2022.

Timeline
27 April 2022
Primary endpoint
10 May 2022
30 May 2022

Quick facts

Lead sponsorRenJi Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment449
Start date27 April 2022
Primary completion10 May 2022
Estimated completion30 May 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

RenJi Hospital

Who can join

18 and older, any sex, with Vaccine Hesitancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

On WeChat platform, through a point-to-point connection, and carry on the questionnaire survey to collect information of liver transplant recipients followed-up by the department of Liver Surgery, Renji Hospital Shanghai Jiao Tong University. Patients meeting inclusion and exclusion criteria will be selected. Conduct statistical analysis to describe the incidence of adverse reactions related to COVID-19 vaccine after liver transplantation, and to compare and evaluate the factors leading to COVID-19 vaccine hesitancy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Investigation on the hesitancy of COVID-19 vaccination among liver transplant recipients: A cross-sectional study in China.
    Pan Y, Gong S, Zhu X, Xue C, et al · · 2022 · cited 5× · PMID 36589975 · DOI 10.3389/fpubh.2022.1014942

Verify or expand the search:

Other recruiting trials for Vaccine Hesitancy

Currently open trials in the same condition.

Other RenJi Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05532592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing